We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Tempus AI's innovative products are transforming the healthcare industry, with a focus on oncology and large market ...

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

AI stocks are red-hot today. Last night Alphabet (Nasdaq: GOOGL) reported earnings and its stock is down 8% today. That ...

Let's explore the Tempus AI stock price and whether it is a good company to buy and hold despite its overvaluation.

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 51,813 call options on the company. This is an increase of approximately ...

Looking at options history for Tempus AI TEM we detected 21 trades. If we consider the specifics of each trade, it is ...